Cyltezo®, first and only FDA-approved Interchangeable biosimilar to Humira®, now commercially available in the U.S.

Cyltezo® (adalimumab-adbm) expands treatment options for patients across multiple chronic inflammatory diseases Cyltezo is the only adalimumab biosimilar with Phase III comparative clinical studies in rheumatoid arthritis, plaque psoriasis and Crohn’s disease RIDGEFIELD, Conn., July 1, 2023 /PRNewswire/ — Boehringer Ingelheim announced today that Cyltezo® (adalimumab-adbm), a U.S. Food and Drug Administration (FDA)-approved Interchangeable biosimilar to Humira® … Read more